Elpetrigine
Anticonvulsant treatment of epileptiform and other neuronal hyperexcitability disorders
- CAS No.
- 212778-82-0
- Indication Class
- CNS / Psychiatry
- Patent Expiry
- To be assessed
- Therapeutic Area
- Neurology
- Target / Mechanism
- SCN2A·SCN3A·CACNA1C·CACNA1S·CACNA1D·+more
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A voltage-gated sodium-channel modulator for epilepsy; antiepileptic demand is stable in emerging markets, suited as a long-term mature product reserve.
Neurology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Elpetrigine is an innovative small molecule drug candidate, classified as a sodium channel blocker. This enables precise regulation of neuronal activity, making it a promising therapeutic agent for treating related neurological diseases.
Supply source: Unibest · Elpetrigine, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.